Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCH014
MIFTS: 57

Schistosomiasis

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Schistosomiasis

About this section

MalaCards integrated aliases for Schistosomiasis:

Name: Schistosomiasis 12 74 52 54 3 15 17 71
Katayama Fever 52 71
Bilharzia 52 3
Schistosoma Mansoni Infection 52
Schistosomiasis Mansoni 71
Blood Fluke 52

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1395
ICD9CM 34 120.8
UMLS 71 C0029827 C0036323 C0036330 more
Sources

Summaries for Schistosomiasis

About this section
NIH Rare Diseases : 52 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species. Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel .

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

CDC : 3 Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Infection with Schistosoma mansoni, S. haematobium, and S. japonicum causes illness in humans; less commonly, S. mekongi and S. intercalatum can cause disease. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide.

Wikipedia : 74 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Sources

Related Diseases for Schistosomiasis

About this section

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 984)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 34.7 IL5 IL4 IL17A IL13 IL10 CD40LG
2 urinary schistosomiasis 34.5 STAT6 RNASE3 IL5 IL4 IL13 IL10
3 portal hypertension 32.0 TNF GPT CD40LG ALB
4 cytokine deficiency 31.6 IL5 IL13
5 paragonimiasis 31.5 RNASE3 IL5 IL13 IGHE
6 fascioliasis 31.4 IL10 IFNG GPT ALB
7 filarial elephantiasis 31.4 IL5 IL4 IL13 IL10
8 strongyloidiasis 31.3 IL5 IL13 IGHE IFNG
9 myelitis 31.3 TNF IL17A IL10 CD40LG
10 cysticercosis 31.3 IL10 IGHE CD40LG
11 transverse myelitis 31.3 TNF IL17A IL10
12 ascaris lumbricoides infection 31.3 IL5 IL13 IL10 IFNG
13 hypersplenism 31.2 IL4 IFNG GPT ALB
14 hypereosinophilic syndrome 31.2 RNASE3 IL5 IL4 IL2 IL13 IL10
15 plague 31.2 TNF IL10 ALB
16 clonorchiasis 31.1 TNF IL2 IL10 IGHE IFNG
17 trichuriasis 31.1 TNF IL13 IL10
18 filariasis 31.1 TNF IL5 IL2 IL10 IGHE IFNG
19 hepatic encephalopathy 31.0 TNF GPT ALB
20 onchocerciasis 31.0 RNASE3 IL5 IL4 IL2 IL13 IGHE
21 appendicitis 30.9 TNF IL2 IL17A IL10 IFNG ALB
22 trichinosis 30.9 IL5 IL4 IL13 IL10 CD40LG
23 cholecystitis 30.9 RNASE3 GPT ALB
24 egg allergy 30.9 IL5 IL4 IL13 IL10 IGHE
25 intestinal obstruction 30.9 TNF GPT ALB
26 opisthorchiasis 30.8 TNF IL4 GPT
27 pyuria 30.8 GPT CD40LG ALB
28 bacterial vaginosis 30.8 TNF IL4 IL1A IL10
29 diarrhea 30.8 TNF IL5 IL2 IL13 IL10 IFNG
30 endomyocardial fibrosis 30.8 TNF RNASE3 IL5 IL4 IL10
31 dysentery 30.7 TNF IL1A IL10 GPT CD40LG ALB
32 cystitis 30.7 TNF IL4 IL2 IL1A IL17A
33 loiasis 30.7 IL5 IL4 IL13 IL10
34 viral hepatitis 30.7 TNF IL4 IL2 IL10 IFNG GPT
35 toxocariasis 30.7 RNASE3 IL5 IL4 IL10 IGHE CD40LG
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 IL17A IL10 IFNG
37 intestinal disease 30.7 TNF IL17A IL10 ALB
38 intestinal tuberculosis 30.7 TNF IFNG ALB
39 chagas disease 30.7 TNF IL4 IL2 IL17A IL10 IFNG
40 echinococcosis 30.6 TNF RNASE3 IL5 IL17A IL10 IGHE
41 disseminated intravascular coagulation 30.6 TNF IL10 GPT
42 hepatitis e 30.6 TNF IFNG GPT CD40LG ALB
43 trachoma 30.6 TNF IL4 IL17A IL10
44 acute cystitis 30.6 TNF IL10 GPT CD40LG ALB
45 toxoplasmosis 30.6 TNF IL5 IL4 IL10 IFNGR1 IFNG
46 urticaria 30.6 TNF RNASE3 IL5 IL4 IL13 IL10
47 salmonellosis 30.6 TNF IL17A IL10 IFNGR1 IFNG GPT
48 plasmodium falciparum malaria 30.6 TNF IL4 IL10 IFNG CD40LG ALB
49 cystic echinococcosis 30.6 IL17A IL10 IGHE IFNG CD40LG
50 amebiasis 30.5 TNF IL4 IL17A CD40LG ALB

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis
Sources

Symptoms & Phenotypes for Schistosomiasis

About this section

MGI Mouse Phenotypes related to Schistosomiasis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ALB ARG1 CD40LG GAPDH IFNG IFNGR1
2 hematopoietic system MP:0005397 10.37 ARG1 CD40LG GAPDH IFNG IFNGR1 IL10
3 immune system MP:0005387 10.33 ALB ARG1 CD40LG IFNG IFNGR1 IL10
4 endocrine/exocrine gland MP:0005379 10.25 ALB CD40LG IFNG IFNGR1 IL10 IL13
5 digestive/alimentary MP:0005381 10.22 ALB IFNG IFNGR1 IL10 IL13 IL17A
6 liver/biliary system MP:0005370 10.18 ALB ARG1 GAPDH IFNG IFNGR1 IL10
7 integument MP:0010771 10.13 CD40LG IFNG IFNGR1 IL10 IL13 IL17A
8 neoplasm MP:0002006 10.02 ALB IFNG IFNGR1 IL10 IL1A IL2
9 renal/urinary system MP:0005367 9.91 ALB CD40LG GAPDH IFNG IFNGR1 IL17A
10 no phenotypic analysis MP:0003012 9.87 IFNG IL10 IL13 IL17A IL2 IL4
11 reproductive system MP:0005389 9.85 CD40LG IFNG IFNGR1 IL10 IL13 IL2
12 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL17A IL2 IL4
13 skeleton MP:0005390 9.32 CD40LG GPT IFNG IFNGR1 IL10 IL13
Sources

Drugs & Therapeutics for Schistosomiasis

About this section

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
3 Artemether, Lumefantrine Drug Combination Phase 4
4
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
5
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
6
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
7
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
8
leucovorin Approved Phase 3 58-05-9 6006 143
9
Triclabendazole Approved, Investigational Phase 3 68786-66-3
10
Tranexamic Acid Approved Phase 3 1197-18-8 5526
11
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
12
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
13
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
14
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
15
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
18
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
19 Trace Elements Phase 3
20 Micronutrients Phase 3
21 Vitamins Phase 3
22 Iron Supplement Phase 3
23 Hematinics Phase 3
24 Nutrients Phase 3
25 Antiprotozoal Agents Phase 3
26 Tubulin Modulators Phase 3
27 Antimitotic Agents Phase 3
28 Fanasil, pyrimethamine drug combination Phase 3
29 Vitamin B Complex Phase 3
30 Folic Acid Antagonists Phase 3
31 Sulfalene Phase 3
32 Folate Phase 3
33 Vitamin B9 Phase 3
34 Hemostatics Phase 3
35 Antifibrinolytic Agents Phase 3
36 Coagulants Phase 3
37 Dermatologic Agents Phase 2, Phase 3
38 Antimalarials Phase 3
39 Antiviral Agents Phase 3
40 Artemisinine Phase 3
41 Artemisinins Phase 3
42
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
43
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
44
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 6474909
45
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
47
Pyronaridine Investigational Phase 2 74847-35-1 5485198
48
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
49
Uric acid Investigational Phase 1, Phase 2 69-93-2 1175
50 Vaccines Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Completed NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
12 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
13 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
14 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Completed NCT01658124 Phase 3 Tranexamic Acid;Placebo
15 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
16 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
17 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
18 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
19 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
20 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
21 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
22 A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
23 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
24 Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection Completed NCT04264130 Phase 2 Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine
25 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
26 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
27 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
28 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
29 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Recruiting NCT03910972 Phase 1, Phase 2
30 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
31 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Not yet recruiting NCT04407507 Phase 2 Ivermectin;Placebo
32 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
33 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
34 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
35 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
36 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
37 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
38 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
39 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Completed NCT03361163 Phase 1
40 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
41 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
42 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
43 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
44 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study） Unknown status NCT02329314
45 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
46 The Effect of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia Unknown status NCT03256123
47 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
48 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
49 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
50 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Oxamniquine
Praziquantel
Sources

Genetic Tests for Schistosomiasis

About this section
Sources

Anatomical Context for Schistosomiasis

About this section

MalaCards organs/tissues related to Schistosomiasis:

40
Liver, Testes, T Cells, Spleen, Skin, Colon, Spinal Cord
Sources

Publications for Schistosomiasis

About this section

Articles related to Schistosomiasis:

(show top 50) (show all 16279)
# Title Authors PMID Year
1
Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. 54 61
20483789 2010
2
Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. 61 54
19717308 2009
3
[The role of TGFbeta1 and IL-13 in cellular signal transduction of hepatic fibrosis of schistosomiasis]. 61 54
20066997 2009
4
Antioxidant status and lipid peroxidation activity in evaluating hepatocellular damage in children. 54 61
20187535 2009
5
Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4. 61 54
19273558 2009
6
Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni. 61 54
19190772 2009
7
Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. 61 54
19072134 2009
8
Genetic polymorphism of glutathione-S-transferase (GST-M1 and GST-T1) in schistosomiasis -associated bladder cancer in Egyptian patients. 61 54
19209780 2008
9
IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease. 54 61
19067841 2008
10
Cytokines, chemokine receptors, CD4+CD25HIGH+ T-cells and clinical forms of human schistosomiasis. 61 54
18534548 2008
11
Discriminating acute from chronic human schistosomiasis mansoni. 54 61
18851939 2008
12
Eosinophil activation status, cytokines and liver fibrosis in Schistosoma mansoni infected patients. 61 54
18550021 2008
13
Eosinophil cationic protein, soluble egg antigen, circulating anodic antigen, and egg excretion in male urogenital schistosomiasis. 54 61
18784236 2008
14
Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. 54 61
18784223 2008
15
Cytokine profile associated with chronic and acute human schistosomiasis mansoni. 61 54
18949326 2008
16
sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica. 61 54
18001742 2008
17
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. 54 61
17631966 2008
18
Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens. 54 61
17426890 2007
19
Schistosome membrane proteins as vaccines. 54 61
17222846 2007
20
The role of chemokines in Schistosoma mansoni infection: insights from human disease and murine models. 54 61
17308793 2006
21
Changes in the humoral immune responses after chemotherapy in single and co-infected individuals with Schisosoma haematobium and Plasmodium falciparum. 61 54
20353134 2006
22
Cloning the genes and DNA binding properties of High Mobility Group B1 (HMGB1) proteins from the human blood flukes Schistosoma mansoni and Schistosoma japonicum. 54 61
16644144 2006
23
Skin test reactivity and Der p-induced interleukin 10 production in patients with asthma or rhinitis infected with Ascaris. 54 61
16729785 2006
24
Some molecular aspects in schistosomiasis mansoni and toxoplasmosis. 54 61
16333889 2005
25
De-glycosylation of Pichia pastoris-produced Schistosoma mansoni cathepsin B eliminates non-specific reactivity with IgG in normal human serum. 61 54
16125194 2005
26
Detection of IgG binding to Schistosoma mansoni recombinant protein RP26 is a sensitive and specific method for acute schistosomiasis diagnosis. 54 61
15710554 2005
27
Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis. 61 54
15725385 2005
28
Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. 54 61
15644127 2005
29
Production of interferon-gamma by natural killer cells and aging in chronic human schistosomiasis. 61 54
15770048 2004
30
[The clinical significance of interferon-gamma and its receptor in patients with schistosomiasis]. 54 61
15830877 2004
31
Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. 54 61
15361241 2004
32
HTLV-1 modifies the clinical and immunological response to schistosomiasis. 61 54
15270862 2004
33
Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E. 61 54
15213147 2004
34
Schistosoma mansoni PIII antigen modulates in vitro granuloma formation by regulating CD28, CTLA-4, and CD86 expression in humans. 54 61
15019278 2004
35
Different cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. 61 54
15724383 2004
36
Clinical and immunological consequences of human T cell leukemia virus type-I and Schistosoma mansoni co-infection. 54 61
15486648 2004
37
Immunoblot analysis of Schistosoma japonicum egg antigens with sera from patients with acute and chronic schistosomiasis japonica. 61 54
15115074 2003
38
Assessment of eosinophil cationic protein as a possible diagnostic marker for female genital schistosomiasis in women living in a Schistosoma haematobium endemic area. 54 61
15053779 2003
39
IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). 54 61
14607968 2003
40
Malaria co-infection in children influences antibody response to schistosome antigens and inflammatory markers associated with morbidity. 61 54
15228260 2003
41
Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis. 54 61
12379664 2002
42
P38 mitogen-activated protein kinase influence on the production of IL-10 in human schistosomiasis mansoni. 54 61
12654092 2002
43
Assessing the morbidity of schistosomiasis by measuring eosinophil cationic protein in serum. 54 61
12214929 2002
44
Polarized Th2 like cells, in the absence of Th0 cells, are responsible for lymphocyte produced IL-4 in high IgE-producer schistosomiasis patients. 54 61
12100735 2002
45
Description of three new polymorphisms in the intronic and 3'UTR regions of the human interferon gamma gene. 54 61
11857052 2002
46
Performance of IgG avidity in an area endemic for schistosomiasis in Egypt. 61 54
15330573 2002
47
Studies on the production and regulation of interleukin, IL-13, IL-4 and interferon-gamma in human Schistosomiasis mansoni. 61 54
12426605 2002
48
Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. 61 54
11756987 2002
49
IgG anti-IgE autoantibodies in visceral leishmaniasis. 54 61
11992157 2002
50
Immunoglobulin-E and anti-IgE treatment in lung disease. 61 54
11980283 2001
Sources

Variations for Schistosomiasis

About this section
Sources

Expression for Schistosomiasis

About this section
Search GEO for disease gene expression data for Schistosomiasis.
Sources

Pathways for Schistosomiasis

About this section

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.08 TNF STAT6 RNASE3 LGMN IL5 IL4
2
ERK Signaling 63
Show member pathways
 13.88 TNF STAT6 IL5 IL4 IL2 IL1A
3
PEDF Induced Signaling 63
Show member pathways
 13.75 TNF IL5 IL4 IL2 IL1A IL17A
4
TGF-Beta Pathway 63
Show member pathways
 13.62 TNF STAT6 IL5 IL4 IL2 IL1A
5
Akt Signaling 63
Show member pathways
 13.5 TNF STAT6 IL5 IL4 IL2 IL1A
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.42 TNF STAT6 IL5 IL4 IL2 IL1A
7
PAK Pathway 63
Show member pathways
 13.38 TNF IL5 IL4 IL2 IL1A IL17A
8
IL-2 Pathway 63
Show member pathways
 13.26 TNF STAT6 IL4 IL2 IL1A IFNGR1
9
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.1 TNF STAT6 IL2 IL10 IFNGR1 IFNG
10
Pathways in cancer 36
12.96 STAT6 IL5 IL4 IL2 IL13 IFNGR1
11
Measles 36
Show member pathways
 12.84 TNF IL2 IL1A IFNGR1 IFNG
12
Immune response NFAT in immune response 22
Show member pathways
 12.76 TNF IL4 IL2 IL10 IGHE IFNGR1
13
4-1BB Pathway 63
Show member pathways
 12.72 TNF IL1A IFNGR1 IFNG CD40LG
14
Immune response IL-23 signaling pathway 22
Show member pathways
 12.69 TNF STAT6 IL2 IL17A IL10 IFNG
15
NF-kappaB Signaling 4
12.66 TNF STAT6 IL4 IL2 IL17A IL10
16
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.65 TNF IL5 IL4 IL13 IGHE
17
T cell receptor signaling pathway 36
Show member pathways
 12.64 TNF IL5 IL4 IL2 IL1A IL17A
18
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.58 TNF IL4 IL2 IFNGR1 IFNG
19
JAK-STAT signaling pathway 36
Show member pathways
 12.57 STAT6 IL5 IL4 IL2 IL13 IL10
20
Allograft rejection 1 36
Show member pathways
 12.48 TNF RNASE3 LGMN IL5 IL4 IL2
21
IL-17 Family Signaling Pathways 64
Show member pathways
 12.45 TNF IL5 IL4 IL17A IL13 IFNG
22
Th17 cell differentiation 36
Show member pathways
 12.43 TNF STAT6 IL5 IL4 IL2 IL1A
23
Folate Metabolism 1
Show member pathways
 12.42 TNF IL4 IL2 IFNG ALB
24
Toxoplasmosis 36
Show member pathways
 12.38 TNF IL4 IL1A IL10 IFNGR1 IFNG
25
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.37 TNF IL5 IL4 IL2 IL1A IL17A
26
Tuberculosis 36
12.34 TNF IL1A IL10 IFNGR1 IFNG
27
Necroptosis 36
Show member pathways
 12.31 TNF STAT6 IL1A IFNGR1 IFNG
28
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.28 TNF IL1A IL13 IL10 GAPDH
29
Bacterial infections in CF airways 22
Show member pathways
 12.24 TNF IL4 IFNGR1 IFNG
30
Spinal Cord Injury 1
12.17 TNF IL4 IL2 IL1A IFNG ARG1
31
Fluid shear stress and atherosclerosis 36
12.16 TNF IL1A IFNG GSTM1
32
Jak Stat Signaling Pathway 66
Show member pathways
 12.14 STAT6 IL4 IL2
33
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.14 TNF IL5 IL4 IL2 IL10 IFNG
34
Osteoclast differentiation 36
12.12 TNF IL1A IFNGR1 IFNG
35
MAPK Pathway 70
Show member pathways
 12.1 IL5 IL2 IL1A IL13
36
IL27-mediated signaling events 1
Show member pathways
 12.09 TNF IL2 IL17A IL10 IFNGR1 IFNG
37
IL12-mediated signaling events 1
Show member pathways
 12.05 STAT6 IL4 IL2 IFNG
38
Interleukin-4 and 13 signaling 65
12.03 TNF STAT6 IL4 IL1A IL17A IL13
39
Amoebiasis 36
12.01 TNF IL10 IFNG ARG1
40
Hematopoietic cell lineage 36
11.99 TNF IL5 IL4 IL1A
41
Rheumatoid arthritis 36
11.96 TNF IL1A IL17A IFNG
42
Glucocorticoid receptor regulatory network 1
11.94 IL5 IL4 IL2 IL13 IFNG
43
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 TNF IL5 IL4 IL2 IFNG CD40LG
44
Dendritic Cells Developmental Lineage Pathway 64
11.85 TNF IL2 IL10 IFNG
45
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.82 TNF IL2 IL1A IFNG CD40LG
46
Pertussis 36
11.79 TNF IL1A IL10
47
IL4-mediated signaling events 1
11.78 STAT6 IL5 IL4 IL10 IGHE CD40LG
48
Lung fibrosis 1
11.77 TNF IL5 IL4 IL13
49
Innate Lymphoid Cells Differentiation 64
11.76 TNF IL5 IL4 IL2 IL17A IL13
50
Interleukin-10 signaling 65
11.71 TNF IL4 IL1A IL13 IL10
Sources

GO Terms for Schistosomiasis

About this section

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF RNASE3 LGMN IL5 IL4 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF IL17A IL13 IGHE CD40LG
3 extracellular space GO:0005615 9.47 TNF RNASE3 IL5 IL4 IL2 IL1A

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF STAT6 IL4 IL2 IL1A IL17A
2 positive regulation of gene expression GO:0010628 10.06 TNF IL4 IL1A IL13 IFNGR1 IFNG
3 inflammatory response GO:0006954 10 TNF IL5 IL1A IL17A IL13 CD40LG
4 cellular response to lipopolysaccharide GO:0071222 9.97 TNF IL1A IL10 ARG1
5 negative regulation of inflammatory response GO:0050728 9.93 IL4 IL2 IL13 IL10
6 B cell differentiation GO:0030183 9.87 IL4 IL10 CD40LG
7 positive regulation of T cell proliferation GO:0042102 9.85 IL4 IL2 CD40LG
8 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL4 IL13 IL10
9 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.8 IL4 IL2 IL1A
10 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL5 IL10
11 positive regulation of tumor necrosis factor secretion GO:1904469 9.73 IL1A IFNGR1 IFNG
12 positive regulation of osteoclast differentiation GO:0045672 9.72 TNF IL17A IFNG
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 TNF IL4 IL2 IL13 IFNG
14 positive regulation of amyloid-beta formation GO:1902004 9.71 TNF IFNGR1 IFNG
15 positive regulation of interleukin-6 secretion GO:2000778 9.71 TNF IL1A IL17A IFNG
16 positive regulation of interleukin-10 secretion GO:2001181 9.7 IL4 IL13
17 positive regulation of mast cell degranulation GO:0043306 9.7 IL4 IL13
18 immune response GO:0006955 9.7 TNF IL5 IL4 IL2 IL1A IL17A
19 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.69 IL4 IL10
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
21 astrocyte activation GO:0048143 9.69 TNF IFNGR1 IFNG
22 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL4 IL2
23 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
24 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
25 type 2 immune response GO:0042092 9.67 IL4 IL10
26 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IL4 IFNG
27 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL2 IL13
28 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
29 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
30 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
31 regulation of immunoglobulin secretion GO:0051023 9.65 TNF CD40LG
32 positive regulation of interleukin-23 production GO:0032747 9.65 IL17A IFNG
33 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNGR1 IFNG
34 positive regulation of cytokine secretion GO:0050715 9.65 TNF IL1A IL10 IFNG GAPDH
35 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 TNF IL10
36 regulation of isotype switching GO:0045191 9.64 IL4 IL10
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL4 IL10 IFNG
38 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
40 positive regulation of isotype switching to IgE isotypes GO:0048295 9.61 STAT6 IL4
41 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.61 TNF IL17A IFNG
42 receptor biosynthetic process GO:0032800 9.6 TNF IL10
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.57 TNF IFNG
45 microglial cell activation GO:0001774 9.55 TNF IL4 IL13 IFNGR1 IFNG
46 cytokine-mediated signaling pathway GO:0019221 9.36 TNF STAT6 IL5 IL4 IL2 IL1A

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL5 IL4 IL2 IL1A IL17A
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL2 IL10
Sources

Sources for Schistosomiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....